Novartis Trims Its Sails, Divests Blood-Testing Unit To Spain’s Grifols
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Joe Jimenez delivers on his strategy to free up resources at Novartis by divesting its non-core blood transfusion diagnostics business for $1.7 billion.